Sodium-4-phenylbuturate (NaPB), a medication used in the management of urea cycle disorders, has been shown to have beneficial effects in patients with PFIC1 and PFIC2 due to increased hepatocanilicular expression of bile salt export pump (BSEP), the protein affected in these conditions [52]. This evidence concerns the gene ABCB11 and urea cycle disorder.